Extracorporeal photochemotherapy – the Columbia Presbyterian experience

Knobler, Elizabeth; Warmuth, Ingrid; Cocco, Carolyn A.; Miller, Barbara J.; MacKay, J. C.

doi:10.1034/j.1600-0781.2002.02762.x

Cited by 31 publications

(19 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent consensus statement from the United Kingdom recommends that all patients with erythrodermic CTCL, either stage III or IVA (major criteria), who have one or more minor criteria of a peripheral blood T-cell clone, more than 10% SCs, and/or CD4/CD8 ratio higher than 10 should be considered for ECP therapy. 160 There are data to suggest that response is better in those who have not been immunosuppressed by chemotherapy (A. Rook, MD, unpublished data) and among those who have a lower blood tumor burden 156,161,162 or the absence of bone-marrow involvement. 158 There is also evidence to show a potential disconnect between clearance of disease in the skin and blood.…”

Section: Extracorporeal Photopheresismentioning

confidence: 95%

Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)

Olsen

Rook

Zic

et al. 2011

Journal of the American Academy of Dermatology

156

135

View full text Add to dashboard Cite

Section: Extracorporeal Photopheresismentioning

confidence: 95%

Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)

Olsen

Rook

Zic

et al. 2011

Journal of the American Academy of Dermatology

156

135

View full text Add to dashboard Cite

“…Based on these criteria, we identified 28 studies, in the majority of cases retrospective and based on single institution series. A total of 407 patients reported as erythrodermic were included (Table ) …”

Section: Extracorporeal Photopheresis For the Treatment Of Erythrodermentioning

confidence: 99%

Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T‐cell lymphoma: a single center clinical experience with long‐term follow‐up data and a brief overview of the literature

et al. 2013

View full text Add to dashboard Cite

Extracorporeal photopheresis (ECP) is a therapeutic procedure in which leukapheresed peripheral blood mononuclear cells are exposed to ultraviolet A in the presence of the photosensitizer 8-methoxypsoralen and then reinfused. Several guidelines recommend ECP as a treatment of choice in erythrodermic primary cutaneous T-cell lymphomas (E-CTCL). However, the level of evidence is low due to the rarity of this disease and the lack of randomized controlled trials. We performed a review of the English literature, restricting our analysis to studies including erythrodermic patients and more than 10 cases. Based on these criteria, we identified 28 studies, with a total of 407 patients. The median response rate in erythrodermic patients was 63% (range 31-86%), with a complete response rate ranging between 0 and 62% (median 20%). In our experience, we treated 51 patients with E-CTCL since 1992. A clinical response was obtained in 32 of 51 patients (63%), with a 16% complete response rate. The median time for response induction was eight months (range: 1-23). The median response duration was 22.4 months (range six months to 11 years). The treatment was generally well tolerated without systemic toxicities grade III-IV. The pretreatment parameters significantly associated with a higher likelihood to obtain a clinical response were the B-score in the peripheral blood, CD4/CD8 ratio, and amount of circulating CD3+CD8+ cells. Literature data together with our personal experience clearly support the clinical activity and tolerability of ECP in patients with E-CTCL. Prospective controlled clinical trials are strongly recommended to better document the evidence.

show abstract

“…Knobler konnte bestätigen,dass erythrodermatische Patienten mit relativ intaktem Immunsystem, d. h. niedrigem CD4:CD8-Verhältnis, optimale Kandidaten für Photopherese sind [19]. Targretin ® wird in einer Dosierung von 300 mg/m 2 täglich per os eingenommen.…”

Section: Photophereseunclassified

Standard- und experimentelle Therapie kutaner T-Zell-Lymphome

Beyeler

Dummer

2003

Der Hautarzt

View full text Add to dashboard Cite

Kutane T-Zell-Lymphome (CTCL) stellen eine heterogene Gruppe lymphoproliferativer Neoplasien dar.Nach der Klassifikation der EORTC (European Organization for Research and Treatment of Cancer ) werden die CTCL in 3 Kategorien eingeteilt:▂ indolente mit einer Überlebenszeit von >10 Jahren, ▂ aggressive mit einer Überlebenszeit von <10 Jahren sowie ▂ provisorisch eingeteilte Formen.Zu den indolenten Formen gehören die Mycosis fungoides mit/ohne follikulärer Muzinose, die pagetoide Retikulose, die lymphomatoide Papulose sowie das groß-zellige CD30-positive Lymphom. Die aggressive Gruppe umfasst das Sézary-Syndrom und das großzellige CD30-negative Lymphom, während elastolytisches Lym- Abkürzungen ADO ArbeitsgemeinschaftDermatologische Onkologie CBCL kutane B-Zell-Lymphome CTCL kutane T-Zell-Lymphome EORTC European Organization for Research and Treatment of Cancer FDA Food and Drug Administration IFN Interferon IL Interleukin MHC "major histocompatibility complex" Standard-und experimentelle Therapie kutaner T-Zell-Lymphomeretinoids and photopheresis have been used for years.Bexarotene is a newly registered drug.To achieve better response rates,several new drugs are being evaluated in clinical trails,including imiquimod,denileukon-diftitox,liposomal doxorubicin,adeno-interferon-γ and various combination approaches. AbstractCutaneous T-cell lymphoma represent a heterogeneous group of diseases characterized by skin invasion of monoclonal T-lymphocytes.These cutaneous T-cell lymphomas are divided into 3 groups based on clinical,histological and immunohistological characteristics: Indolent with a survival time of over 10 years,aggressive with a survival time less than 10 years and provisional (EORTC classification).Standard treatments such as PUVA,total skin electron beam, methotrexate,polychemotherapy regimens,

show abstract

Extracorporeal photochemotherapy – the Columbia Presbyterian experience

Cited by 31 publications

References 30 publications

Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)

Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)

Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T‐cell lymphoma: a single center clinical experience with long‐term follow‐up data and a brief overview of the literature

Standard- und experimentelle Therapie kutaner T-Zell-Lymphome

Contact Info

Product

Resources

About